Document text
Principal Investigator: Matthew Hall
Organization: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
Fiscal Year: 2023
Award: $2,626,150
Funding agency: National Center for Advancing Translational Sciences
During this past reporting period, NCATS worked towards completing a number of SARS-CoV-2 assays, including target-based and live virus assays, to screen for potential hits against SARS-CoV-2. Optimized assays were screened against a panel of drug repurposing, clinical candidate and antiviral libraries that have been assembled at NCATS. These results have been made freely available to public with unprecedented speed through the NCATS OpenData Portal and through a number of preprint/journal publications.
The COVID-19 pandemic continued to be a pressing public health emergency garnering rapid response from scientists across the globe, and NCATS scientists have concluded screening and drug repurposing against a number of SARS-CoV-2-related targets in response. Completed screens are listed below as (1-4), and screening in development is listed in (5).
1) SARS-CoV-2 entry into target cells is initiated through direct binding of the viral spike protein to the host receptor ACE2. Members of this team developed a proximity-based AlphaLISA assay to measure binding of SARS-CoV-2 spike RBD protein to ACE2 and used it to run a drug-repurposing screen, yielding 25 high-quality, small-molecule hits worthy of follow-up in cell-based models. This established AlphaLISA RBD-ACE2 platform allows scientists to evaluate disruption of this viral-host interaction, and this assay has been reported at multiple conferences.
2) The TMPRSS2 enzyme has been shown to be critically important for priming SARS-CoV-2 for viral entry into host lung cells, yet no SARS-CoV-2-related biochemical assay for this target had been previously reported. To enable inhibitor discovery and profiling of FDA-approved therapeutics, this team developed a biochemical assay using recombinant TMPRSS2 suitable for high-throughput screening applications. The team validated this important assay and demonstrated effectiveness to quantify inhibition down to subnanomolar concentrations using clinically approved proteases. This TMPRSS2 work will enable further screening against this important antiviral host target, and provide insight into selectivity and potency of repurposing candidates.
3) Antibodies that physically block SARS-CoV-2 entry into host cells (i.e. antibody-mediated viral neutralization) may provide leads for further therapeutic development. This project team used an innovative combination of humanized nanobody library and enrichment strategies (also known as phage panning) to discover several clones of antibodies capable of high-affinity binding to SARS-CoV-2 spike protein. Because these highly engineered antibody variants already incorporate beneficial features such as similarity to human antibodies, they are expected to be developed into viable therapeutic leads faster than other types of neutralizing antibodies.
4) Pulmonary fibrosis is a major problem associated with severe cases of SARS-CoV-2 infections and the leading cause of mortality associated with COVID-19. Currently, the only treatment is supplemental oxygen and mechanical ventilation to hospitalized COVID patients. There is no effective therapeutic measure to mitigate the disease. The project's goal is to develop small molecular inhibitors as therapeutic measures to mitigate COVID-19 associated lung fibrosis. During this period, we tried to optimize the absorbance-based assay developed in our collaborator's lab and develop a fluorescence-based thrombin activity assay.
5) The National Cancer Institutes (NCI) Natural Products Repository is one of the largest natural products representing a rich and highly diverse set of bioactives in fractionated extracts that are amenable for high throughput screening. Currently there are over 500,000 partially purified natural product fractions available through this collection, with over 1,000,000 partially purified natural product fractions planned. This library has previously not been explored for anti-replication activity against SARS-CoV-2. To enable screening of the NCI Natural Products Repository, we have optimized a previously developed firefly luciferase SARS-CoV-2 live virus assay, as well as have developed a secondary no-wash, Mcherry SARS-CoV-2 assay that enables both toxicity and infection reads in the same well. In addition, we have built a dedicated BSL-3 high throughput screening facility for automated screening of antivirals against SARS-CoV-2 and other pathogens. The NCATS APP BSL-3 HTS Platform is a fully-automated, robotic high throughput screening in 384/1536w assay plates for high containment pathogens (e.g. SARS-CoV-2) that was built inside a BSL-3. This NCATS Installed Enclosure Design Filtration Microzone (DFMZ) contains a customized HTS robotics platforms including, 90 ft2; 540 ft3 (interior space) that is rated for BSL3 level pathogens due to the presence of a Class II Automation Enclosure, inward continuous unidirectional airflow, HEPA- filtered, and minimu34m ISO 5 conditions within the work zone. In addition, the automated platform has necessary components for compound library dispensing including an Echo 655 acoustic dispenser, a V-spin centrifuge, a PlateLoc sealer, and a X-peel peeler, as well as integrated liquid handling including a BioTek EL406 and Certus Flex, and components for integrated screening including a Cytomat incubator which can hold 200 HTS cell plates and a multimode reader, the BMG Pherastar, which equipped with a stacker and a range of filters for multi-assay formats, and an integrated robotics arm.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><ACE2><Acoustic><Acoustics><Active Follow-up><Address><Affinity><Air Movements><Antibodies><Antiviral Agents><Antiviral Drugs><Antivirals><Assay><Automation><Bacteriophages><Binding><Bioassay><Biochemical><Biologic Assays><Biological Assay><Biology><COVID associated pneumonia><COVID crisis><COVID epidemic><COVID induced pneumonia><COVID infected patient><COVID pandemic><COVID patient><COVID pneumonia><COVID positive patient><COVID related pneumonia><COVID-19><COVID-19 S protein><COVID-19 assay><COVID-19 associated pneumonia><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 induced pneumonia><COVID-19 infected patient><COVID-19 infection><COVID-19 pandemic><COVID-19 patient><COVID-19 pneumonia><COVID-19 positive patient><COVID-19 public health crisis><COVID-19 related pneumonia><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 therapeutics><COVID-19 virus><COVID-19 virus infection><COVID19><COVID19 S protein><COVID19 assay><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 pandemic><COVID19 patient><COVID19 positive patient><COVID19 public health crisis><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 therapeutics><COVID19 virus><CV-19><CV19><Cell Body><Cells><Clinical><CoV-2><CoV2><Collection><Communities><Containment><Data><Dedications><Development><Disease><Disorder><Drugs><Effectiveness><Enzyme Gene><Enzymes><Epitheliasin Gene><Esteroproteases><FDA approved><Filtration><Filtration Fractionation><Firefly Luciferases><Fluorescence><Goals><HEPA Filter><HEPA Filtration><HEPA cleaner><High Throughput Assay><Hospital Admission><Hospitalization><Human><Incubators><Infection><Investigators><Journals><Libraries><Liquid substance><Lung><Lung Respiratory System><Lung Tissue Fibrosis><Magazine><Measures><Mechanical ventilation><Mediating><Medication><Modeling><Modern Man><Molecular Interaction><NCATS><NCI Organization><National Cancer Institute><National Center for Advancing Translational Sciences><Natural Products><PRSS10><Peptidases><Peptide Hydrolases><Phages><Pharmaceutic Preparations><Pharmaceutical Preparations><Photinus luciferin 4 monooxygenase><Position><Positioning Attribute><Printing><Protease Gene><Proteases><Proteinases><Proteins><Proteolytic Enzymes><Public Health><Publications><Pulmonary Fibrosis><Reader><Receptor Protein><Recombinants><Reporting><Research Activity><Research Personnel><Research Priority><Research Resources><Research Support><Researchers><Resources><Robotics><Running><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 assay><SARS-CoV-2 associated pneumonia><SARS-CoV-2 entry inhibitor><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 induced pneumonia><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV-2 patient><SARS-CoV-2 pneumonia><SARS-CoV-2 positive patient><SARS-CoV-2 related pneumonia><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 therapeutics><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 therapeutics><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Scientific Publication><Scientist><Screening Result><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 entry inhibitor><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 therapeutics><Severe acute respiratory syndrome related corona virus 2><Site><Societies><Speed><TMPRSS2><TMPRSS2 gene><Testing><Therapeutic><Therapeutic Intervention><Thrombase><Thrombin><Toxic effect><Toxicities><Translational Research><Translational Science><Translations><Vaccines><Variant><Variation><Viral><Viral Activity><Viral Function><Viral Physiology><Virus><Work><Wuhan coronavirus><active followup><air flow><airflow><angiotensin converting enzyme 2><angiotensin converting enzyme II><anti-viral agents><anti-viral compound><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-virals><antibody engineering><antiviral compound><antiviral medication><antiviral therapeutic><arm><assay development><atypical pneumonia><bacterial virus><beta CoV><beta coronavirus><betaCoV><betacoronavirus><block SARS-CoV-2 entry><block severe acute respiratory syndrome coronavirus 2 entry><clinical candidate><clinical efficacy><conference><convention><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 assay><coronavirus disease 2019 associated pneumonia><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 induced pneumonia><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 patient><coronavirus disease 2019 pneumonia><coronavirus disease 2019 positive patient><coronavirus disease 2019 public health crisis><coronavirus disease 2019 related pneumonia><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 therapeutics><coronavirus disease 2019 virus><coronavirus disease associated pneumonia><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease induced pneumonia><coronavirus disease infected patient><coronavirus disease pandemic><coronavirus disease patient><coronavirus disease pneumonia><coronavirus disease positive patient><coronavirus disease related pneumonia><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 patient><coronavirus disease-19 pneumonia><coronavirus disease-19 virus><coronavirus infectious disease-19><coronavirus patient><depository><design><designing><developmental><drug repurposing><drug/agent><effective therapy><effective treatment><fibrinogenase><fibrosis in the lung><fluid><follow up><follow-up><followed up><followup><hCoV19><high efficiency particulate air cleaner><high efficiency particulate air filter><high throughput screening><high-efficiency particulate air purifier><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><inhibit SARS-CoV-2 entry><inhibit severe acute respiratory syndrome coronavirus 2 entry><inhibitor><innovate><innovation><innovative><insight><intervention therapy><liquid><lung fibrosis><mechanical respiratory assist><mechanically ventilated><member><mortality><nCoV2><nano-molar><nanobodies><nanobody><nanomolar><naturally occurring product><neutralizing antibody><novel><pandemic><pandemic disease><pathogen><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><pneumonia due to COVID><pneumonia due to COVID-19><pneumonia due to SARS-CoV-2><pneumonia due to coronavirus disease><pneumonia due to coronavirus disease 2019><pneumonia due to severe acute respiratory syndrome coronavirus 2><pneumonia in COVID><pneumonia in COVID-19><pneumonia in SARS-CoV-2><pneumonia in coronavirus disease><pneumonia in coronavirus disease 2019><pneumonia in severe acute respiratory syndrome coronavirus 2><public health emergency><pulmonary><receptor><repository><repurposing agent><repurposing medication><response><screening><screenings><sdAb><severe acute respiratory syndrome coronavirus 2 assay><severe acute respiratory syndrome coronavirus 2 associated pneumonia><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 induced pneumonia><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 pneumonia><severe acute respiratory syndrome coronavirus 2 positive patient><severe acute respiratory syndrome coronavirus 2 related pneumonia><single domain antibodies><small molecular inhibitor><small molecule><summit><supplemental oxygen><symposia><symposium><therapeutic agent development><therapeutic development><therapeutically effective><therapeutics against COVID-19><therapeutics against COVID19><therapeutics against SARS-CoV-2><therapeutics against SARS-coronavirus-2><therapeutics against Severe acute respiratory syndrome coronavirus 2><therapeutics against coronavirus disease 2019><therapeutics for novel coronavirus><translation><translation research><translational investigation><β CoV><β coronavirus><βCoV>